跳至主要内容
临床试验/NCT03440697
NCT03440697
进行中(未招募)
不适用

Pathogenetic Basis of Aortopathy and Aortic Valve Disease

Yale University2 个研究点 分布在 1 个国家目标入组 3,000 人2015年12月10日

概览

阶段
不适用
干预措施
Controls- Closed to external enrollment
疾病 / 适应症
Aortopathies
发起方
Yale University
入组人数
3000
试验地点
2
主要终点
Genetic Analysis
状态
进行中(未招募)
最后更新
2个月前

概览

简要总结

The main purpose of this study is to define the complex genetic and pathogenic basis of thoracic aortic aneurysm (TAA) and other forms of aortopathy and/or aortic valve disease by identifying novel disease-causing genes and by identifying important genetic modifiers for aortic and aortic valve disease severity.

详细描述

Thoracic aortic aneurysm (TAA) is a type of aortopathy describing dilation of the proximal aortic dimensions including the aortic root, which is a risk factor for aortic dissection and sudden cardiac death. TAA and other forms of aortopathy (e.g. aortic tortuosity or aortic hypoplasia/stenosis) develop in the presence or absence of additional cardiovascular malformations including bicuspid aortic valve. TAA is associated with connective tissue disorders (e.g. Marfan syndrome), and familial clustering has been identified in a significant proportion of nonsyndromic cases, establishing high heritability. Pedigree analysis of TAA kindreds clearly identifies complex inheritance; however, progress towards understanding the genetic basis of TAA and other forms of aortopathy and, ultimately, the susceptibility to aortic dissection remains incomplete. There is a clinical need to develop novel methods for predicting disease risk based on genotype and phenotype, to further elucidate the genetic and pathogenic mechanisms of aortopathy, and to improve medical and surgical therapies. The overarching hypothesis of this study is that individual genetic variation modulates susceptibility to disease severity and progression. The goals of this study are 1) to ascertain a cohort of subjects who have aortopathy and/or aortic valve disease including TAA or who have genetic risk for the development of aortopathy and/or aortic valve disease, 2) to collect paired blood and tissue samples from well-characterized subjects, family members of subjects, and controls to perform genome-wide DNA sequence, histopathologic, transcriptional, and proteomic analyses, and 3) to establish a tissue biorepository with detailed phenotype information to facilitate a broad spectrum of current and future studies.

注册库
clinicaltrials.gov
开始日期
2015年12月10日
结束日期
2030年12月31日
最后更新
2个月前
研究类型
Observational
性别
All

研究者

责任方
Sponsor
主要研究者

Benjamin Landis

Associate Professor of Pediatrics

Indiana University

入排标准

入选标准

  • Open to external enrollment:
  • Subjects with a genetic diagnosis of Marfan Syndrome (MDS), Loeys-Dietz Syndrome (LDS), or Vascular Ehlers-Danlos Syndrome (EDS); (Positive genetic testing or a previous cardiac study required to be eligible)
  • Family members of eligible subjects (Only family members of subjects with syndromic diagnoses are eligible for external enrollment at this time)
  • Closed to external enrollment:
  • Subjects with aortic disease including TAA\* or dissection, aortic tortuosity, or aortic hypoplasia/stenosis (based on any cardiac imaging modality including echocardiography, CT, MRI, or angiography)
  • Subjects with aortic valve disease (bicuspid, unicuspid, or tricuspid disease)
  • Control subjects having tissue removed during a surgical procedure (e.g. coronary artery bypass graft surgery (CABG), cardiac transplant, etc.)

排除标准

  • Inability or unwillingness to provide consent (assent when indicated)

研究组 & 干预措施

Controls- Closed to external enrollment

Control subjects having tissue removed during a surgical procedure (e.g. coronary artery bypass graft surgery (CABG), cardiac transplant, etc.)

Aortopathy- Closed to external enrollment

Subjects with aortic disease including TAA or dissection, aortic tortuosity, or aortic hypoplasia/stenosis (based on any cardiac imaging modality including echocardiography, CT, MRI, or angiography)

Syndromic- Open to external enrollment

Subjects with a genetic diagnosis of Marfan Syndrome (MFS), Loeys-Dietz Syndrome (LDS), Vascular Ehlers-Danlos Syndrome (EDS) •positive genetic testing and/or a previous cardiac study required to be eligible

Aortopathy with Positive Genetic Results- Open to Enrollment

Subjects with aortic disease including TAA or dissection, aortic tortuosity, or aortic hypoplasia/stenosis (based on any cardiac imaging modality including echocardiography, CT, MRI, or angiography) who also have positive genetic testing results related to aortopathy.

Aortic Valve Disease- Closed to enrollment

Subjects with aortic valve disease (bicuspid, unicuspid, or tricuspid disease)

Family Members- Open to external enrollment

Family members of eligible subjects •Only family members of subjects with syndromic diagnoses are eligible for external enrollment at this time

结局指标

主要结局

Genetic Analysis

时间窗: 20 years

The mechanisms of TAA pathogenesis will be determined by studying explanted aortic tissue and cells derived from patients with TAA for gene expression, protein expression, and other functional assays.

Biorepository Establishment

时间窗: 20 years

Establish a biorepository with detailed phenotype information to facilitate a broad spectrum of current and future studies

研究点 (2)

Loading locations...

相似试验